Anteris Technologies Global Corp. (NASDAQ:AVR - Get Free Report) major shareholder L1 Capital Pty Ltd bought 272,695 shares of the business's stock in a transaction dated Tuesday, October 6th. The shares were bought at an average cost of $7.18 per share, for a total transaction of $1,957,950.10. Following the purchase, the insider directly owned 6,358,271 shares in the company, valued at approximately $45,652,385.78. This represents a 4.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
L1 Capital Pty Ltd also recently made the following trade(s):
- On Monday, October 5th, L1 Capital Pty Ltd purchased 648,455 shares of Anteris Technologies Global stock. The stock was bought at an average cost of $7.51 per share, with a total value of $4,869,897.05.
- On Friday, October 2nd, L1 Capital Pty Ltd acquired 236,354 shares of Anteris Technologies Global stock. The stock was bought at an average price of $7.78 per share, with a total value of $1,838,834.12.
- On Thursday, October 1st, L1 Capital Pty Ltd acquired 322,940 shares of Anteris Technologies Global stock. The shares were purchased at an average cost of $7.60 per share, for a total transaction of $2,454,344.00.
- On Wednesday, September 30th, L1 Capital Pty Ltd purchased 74,286 shares of Anteris Technologies Global stock. The shares were purchased at an average price of $7.72 per share, for a total transaction of $573,487.92.
- On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.83, for a total transaction of $68,874.00.
- On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.30, for a total transaction of $3,495,079.50.
- On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.10, for a total transaction of $2,291,780.40.
- On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total value of $1,415,240.10.
- On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.30, for a total value of $3,989,046.40.
- On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.23, for a total value of $120,001.63.
Anteris Technologies Global Price Performance
Shares of AVR traded down $0.19 during trading hours on Thursday, hitting $6.63. The stock had a trading volume of 2,470,247 shares, compared to its average volume of 1,098,027. The firm has a market capitalization of $646.16 million, a PE ratio of -3.40 and a beta of 1.87. Anteris Technologies Global Corp. has a 12 month low of $3.30 and a 12 month high of $11.06. The stock has a fifty day moving average price of $8.41 and a 200 day moving average price of $8.03.
Anteris Technologies Global (NASDAQ:AVR - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.09). The firm had revenue of $1.01 million for the quarter, compared to the consensus estimate of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same quarter in the prior year, the firm earned ($0.58) earnings per share. As a group, analysts anticipate that Anteris Technologies Global Corp. will post -1.21 EPS for the current fiscal year.
Institutional Trading of Anteris Technologies Global
Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Anteris Technologies Global in the second quarter worth about $56,846,000. Nantahala Capital Management LLC purchased a new stake in shares of Anteris Technologies Global during the 2nd quarter worth approximately $33,325,850. ADAR1 Capital Management LLC bought a new position in shares of Anteris Technologies Global during the 2nd quarter valued at approximately $30,979,000. Perceptive Advisors LLC grew its holdings in shares of Anteris Technologies Global by 104.4% in the first quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company's stock valued at $19,011,000 after purchasing an additional 1,750,000 shares in the last quarter. Finally, Militia Capital Management LLC bought a new stake in Anteris Technologies Global in the first quarter worth $3,663,000.
Analyst Ratings Changes
A number of brokerages have recently issued reports on AVR. Weiss Ratings reissued a "sell (d-)" rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Barclays upgraded Anteris Technologies Global to a "hold" rating in a research note on Wednesday. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $15.00 price target on shares of Anteris Technologies Global in a report on Friday, August 14th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $14.00.
Read Our Latest Report on Anteris Technologies Global
Anteris Technologies Global Company Profile
(
Get Free Report)
Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company's lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.
Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.
The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Anteris Technologies Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anteris Technologies Global wasn't on the list.
While Anteris Technologies Global currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.